Navigation Links
Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Date:4/22/2008

equal to 30 days) or late (> 30 days), whether analyzed per protocol or by the Academic Research Consortium (ARC) definition. Rates of definite/probable late stent thrombosis at one year under the ARC definition were 0.5 percent for XIENCE V and 0.6 percent for TAXUS. The ARC definition of late stent thrombosis was developed to eliminate variability in the definitions across various drug eluting stent trials.

In addition, the reduction in in-segment late loss at eight months with XIENCE V compared to TAXUS was consistent across a variety of subgroups in the SPIRIT III trial; however, the SPIRIT III trial was underpowered to measure statistical differences in any of the subgroups.

The SPIRIT III nine-month results were previously reported in March 2007 at the American College of Cardiology's 56th Annual Scientific Session, and the one-year results were previously reported in October 2007 at the Transcatheter Cardiovascular Therapeutics scientific symposium. The SPIRIT III two-year results will be presented in mid-May at EuroPCR 2008 in Barcelona, Spain.

About the SPIRIT III Trial

SPIRIT III is a prospective, multi-center, randomized, single-blind, controlled clinical trial comparing XIENCE V to TAXUS in 1,002 patients (669 XIENCE V patients, 333 TAXUS patients) with either one or two de novo native coronary artery lesions. The trial was conducted across 65 academic and community-based centers in the United States between June 22, 2005 and March 15, 2006. The primary endpoint was in-segment late loss at eight months and the major secondary (co-primary) endpoint was TVF at nine months. An additional pre-specified secondary endpoint included MACE at nine months and one year.

About XIENCE V

The XIENCE V stent system utilizes everolimus, which has been shown to reduce tissue proliferation in the coronary vessels following stent implantation, and is based upon the highly deliverable and proven MULTI-LINK VISION(R) coronary stent p
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
2. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
3. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
4. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
5. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
8. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
9. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... 10, 2014  Breg, Inc., a premier provider ... the FreeRunner™ knee brace with new innovations to ... mal-tracking return to active lifestyles.  FreeRunner,s patent-pending design ... providing support when patients need it most, and ... Patellofemoral issues are the most common ...
(Date:7/10/2014)... Utah , July 10, 2014  BC Technical, ... and MiE America , Inc., a leading provider ... entered into a long-term agreement naming BC Technical as ... US. MiE and BC Technical announced ... agreement to establish BC Technical as the service and ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... Sept. 12, 2011 International Isotopes Inc (OTC Bulletin Board: ... an update of the Company,s general business status, particularly, the ... well as to discuss progress of its ongoing plans for ... Isotopes Inc General Business Update. When: ...
... Lewis County today launched a new program to help ... Through a partnership with the National Association of Counties (NACo), ... a card that offers an average of 24 percent savings ... The card can be used by those who do not ...
Cached Medicine Technology:International Isotopes Inc Announces Conference Call to Give an Update on the Company's General Business Status 2Lewis County Introduces Prescription Discount Card to Help Alleviate High Costs 2
(Date:7/14/2014)... 2014 According to the ... recently updated by Vkool.com, this is a ... range of simple and easy tips for ...     Increasing omega-3 fatty acids ... ,     Increasing fiber ,     Avoid ...
(Date:7/14/2014)... 14, 2014 Vaginal Mesh lawsuit ... seven different pelvic mesh manufacturers in the U.S. District ... Schulte LLC. The federal complaints are pending against pelvic ... American Medical Systems (MDL No. 2325), and C.R. Bard, ... are 58,262 Vaginal Mesh lawsuit claims pending, according to ...
(Date:7/14/2014)... July 14, 2014 Doctor Mike Hamilton ... launch of their new company website. The Inception website ... information on chiropractic marketing. It's also a place for ... has to offer. , When contacted at his office, ... version of our main website. Our site is obviously ...
(Date:7/14/2014)... Texas (PRWEB) July 14, 2014 ... forefront in complete spine care—from diagnosis to treatment and ... locations are either certified in or training for certification ... Theresa Adame, have recently completed the extensive program. , ... utilizing The McKenzie Method results in better outcomes for ...
(Date:7/14/2014)... Sacramento, CA (PRWEB) July 14, 2014 ... a new office in Sacramento. The announcement has been made ... the office. In addition, the announcement has been made in ... their dental services in the Sacramento area. , Crystal Dental ... procedures. Some of the services offered by Crystal Dental include ...
Breaking Medicine News(10 mins):Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 2Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5Health News:Doctor Mike Hamilton From Inception Chiropractic Websites Announces the Launch of Their New Website 2Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 2Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 3Health News:Crystal Dental Announces the Opening of New Office Location in Sacramento 2
... May 29 The following is a,statement by Matthew ... World Health Organization,s World No Tobacco Day, to be ... toll of the global,tobacco epidemic and the urgent need ... and save lives., This year,s theme -- Tobacco-Free ...
... Area ... hospitals, PLANO, Texas, May ... in Chicago,Illinois, has extended its relationship with the global information,technology provider. Perot ... ago, and in that period of,time its team of revenue cycle professionals ...
... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today ... of Stockholders Thursday, June 12, 2008 at 1:00,p.m. ... Hale & Dorr, 60 State,Street, Boston, MA., ... Pharmaceuticals, Inc., Alseres Pharmaceuticals, Inc. (ALSE) is ...
... patients who suffer a heart attack never have any warning ... problem is noncalcified plaque, a buildup of soft deposits embedded ... angiography or cardiac stress tests and prone to rupture ... success in detecting and measuring noncalcified plaque. In a pilot ...
... University Massey Cancer Center researchers have identified that a ... chronic myelogenous leukemia cells previously resistant to conventional forms ... a cancer of the bone marrow caused by a ... common forms of leukemia. Imatinib mesylate, or Gleevec, is ...
... N.J., May 29 The Musculoskeletal Transplant,Foundation (MTF) ... needed for cartilage and joint repair for injured ... be given priority in obtaining,tissue used for cartilage ... in short supply, these types of tissue are ...
Cached Medicine News:Health News:World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives 2Health News:World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives 3Health News:Perot Systems and Sinai Health System Extend Revenue Cycle Solutions Contract 2Health News:Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting 2Health News:New method effective in detecting dangerous coronary plaque 2Health News:New method effective in detecting dangerous coronary plaque 3Health News:Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy 2
Full Handle Laseredge Spoon Blade Knife, 3.0 mm angled double bevel. Blade dimension: 11.0 mm (L) x 3.0 mm (W). Cut: 320....
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 3.2 mm straight. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Medicine Products: